Premium
Prenatal high‐dose immunoglobulin treatment for neonatal hemochromatosis: A case report and review of the literature
Author(s) -
Tanaka Hirokazu,
Haba Reiji,
Itoh Susumu,
Sakamoto Haruhiko,
Hata Toshiyuki
Publication year - 2011
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/j.1447-0756.2011.01680.x
Subject(s) - medicine , hemochromatosis , antibody , pediatrics , obstetrics , immunology
Neonatal hemochromatosis is a difficult disorder to cure, and it has a high rate of recurrence. High‐dose immunoglobulin treatment is very effective as prenatal treatment for recurrent neonatal hemochromatosis. A 34‐year‐old pregnant Japanese woman underwent high‐dose immunoglobulin treatment for recurrent neonatal hemochromatosis. High‐dose non‐specific intravenous immunoglobulin (1 g/kg bodyweight) was administered to the mother intravenously every week from 18 until 36 gestational weeks. A male infant was delivered at 37 weeks of gestation, and his condition was favorable, including hepatic function. The use of γ‐globulin for neonatal hemochromatosis appears adequately validated by experience.